GO
Loading...

Sanofi SA

More

  • Midday movers: Hess, Twitter, Valero Eneregy & More Wednesday, 30 Jul 2014 | 12:14 PM ET

    Some of Wednesday's midday movers:

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • BEIJING, July 28- Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.

  • Summer's busiest week for markets is here Friday, 25 Jul 2014 | 6:10 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.

  • *Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.

  • LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.

  • *Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.

  • *Sanofi mulls fate of 200 older drugs including Plavix. *Sanofi also held talks with TPG and Warburg Pincus. PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.

  • Sanofi mulls selling mature drug portfolio: Report Wednesday, 16 Jul 2014 | 8:39 AM ET

    Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.

  • PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.

  • *Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.

  • July 15- Hewlett-Packard Co interim Chairman and activist investor Ralph Whitworth will step down on Wednesday to focus on his health, the latest top-level departure from the computer maker as it struggles to return to consistent growth.

  • July 15- Hewlett-Packard Co interim chairman and activist investor Ralph Whitworth will step down on Wednesday to focus on his health, the latest top-level departure from the computer maker as it struggles to return to consistent growth.

  • July 15- Hewlett-Packard Co said interim Chairman Ralph Whitworth resigned from its board of directors, effective Wednesday, to focus on his health. Relational Investors said co-founder Whitworth was taking a leave of absence from the hedge fund and it wished "his family all the best at this difficult time."

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • *Move aimed towards making drugs more affordable in India. MUMBAI, July 14- India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • MUMBAI, July 14- India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • July 11- Big Pharma companies are trying to offload low-growth, mature drug portfolios to firms such as Blackstone Group LP and TPG Capital LP which need to figure out how to carve them out, in one of private equity's greatest dealmaking challenges.

  • Sanofi dengue vaccine promising but questions remain Thursday, 10 Jul 2014 | 7:01 PM ET

    PARIS, July 11- The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

  • Early movers: UNH, BAC, IBM, COST, LL, WDFC & more Thursday, 10 Jul 2014 | 7:48 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.